For clinical practice: Among novel serological markers, 14-3-3η protein offers the strongest validation and commercial availability for seronegative early arthritis triage [23,24,25]; its addition to RF and ACPA testing improves diagnostic sensitivity meaningfully without substantial loss of specificity, though it remains absent from current ACR/EULAR classification criteria. This evidence concerns the gene PRTN3 and arthritic joint disease.